Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.36 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.36 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 3/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30056844 | 1.00 | GABRP (0.36) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL21055204 | 0.85 | GABRP (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL26685643 | 0.80 | JAK2 (0.37) | JAK2PDPK1AXLDYRK1AIDO1 | |
| SCHEMBL14895511 | 0.80 | GABRP (0.38) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL31543243 | 0.80 | JAK2 (0.37) | JAK2PDPK1AXLDYRK1AIDO1 | |
| SCHEMBL12466691 | 0.78 | JAK2 (0.44) | JAK2PDPK1DYRK1AGSK3BMAPK1 | |
| SCHEMBL30872191 | 0.77 | GABRP (0.36) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL14895721 | 0.77 | GABRP (0.36) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29562995 | 0.77 | ADORA2A (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL16580770 | 0.77 | ADORA2A (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242880-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE | MY-T BIO LIMITED (GB) | 2025-11-27 | — | — | WO | disclosed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4563579-A1 | MACROCYCLIC EGFR INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024022286-A1 | MACROCYCLIC EGFR INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海和誉生物医药科技有限公司 | 2024-02-01 | — | — | WO | disclosed |
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | THESEUS PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | THESEUS PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | THESEUS PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| CN-115551868-A | Macrocyclic compounds and uses thereof | 特修斯制药公司 | 2022-12-30 | — | — | CN | disclosed |
| US-11247990-B1 | Bicyclic fused pyridine compounds as inhibitors of TAM kinases | ARRAY BIOPHARMA INC (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2019113190-A1 | BICYCLIC FUSED PYRIDINE COMPOUNDS AS INHIBITORS OF TAM KINASES | ARRAY BIOPHARMA INC. (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | EGFR, ERBB2, ERBB3 | GABRP 3800/4885GABRD 4030/4885GABRA1 2999/4885 |
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | GABRP 2112/4885GABRD 2665/4885GABRA1 1258/4885 |
| US-11247990-B1 | Bicyclic fused pyridine compounds as inhibitors of TAM kinases | MAP3K1, MAP3K3, MAP3K2 | GABRP 1408/4885GABRD 3195/4885GABRA1 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.